View Past PerformanceHyper バランスシートの健全性財務の健全性 基準チェック /16Hyperの総株主資本は₩15.3B 、総負債は₩36.3Bで、負債比率は237.1%となります。総資産と総負債はそれぞれ₩71.9Bと₩56.6Bです。主要情報237.08%負債資本比率₩36.30b負債インタレスト・カバレッジ・レシオn/a現金₩18.23bエクイティ₩15.31b負債合計₩56.62b総資産₩71.94b財務の健全性に関する最新情報分析記事 • Dec 01Is Hyper (KOSDAQ:065650) A Risky Investment?David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...分析記事 • Jun 26We Think Hyper (KOSDAQ:065650) Has A Fair Chunk Of DebtDavid Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...分析記事 • Nov 29Despite Lacking Profits Medifron DBT (KOSDAQ:065650) Seems To Be On Top Of Its DebtSome say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...すべての更新を表示Recent updatesNew Risk • Apr 03New major risk - Financial positionThe company's debt is not well covered by operating cash flow. Currently running at an operating cash loss. This is considered a major risk. If the company's operating cash flows are too small relative to the size of their debt, it increases their balance sheet risk. The company has less cash from operations to cover its expenses from servicing large debt and it increases the risk of liquidity issues. It also extends the time it would take for the company to pay back the debt in full, meaning it may not be able to easily pay it all off in a distress scenario. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (currently running at an operating cash loss). High level of non-cash earnings (31% accrual ratio). Shareholders have been substantially diluted in the past year (64% increase in shares outstanding). Minor Risk Market cap is less than US$100m (₩43.1b market cap, or US$28.6m).New Risk • Mar 26New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 64% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 34% per year over the past 5 years. Shareholders have been substantially diluted in the past year (64% increase in shares outstanding). Minor Risk Market cap is less than US$100m (₩43.2b market cap, or US$28.7m).お知らせ • Mar 17Hyper Corporation Inc., Annual General Meeting, Mar 31, 2026Hyper Corporation Inc., Annual General Meeting, Mar 31, 2026, at 09:01 Tokyo Standard Time. Location: conference room, 637, eonju-ro, gangnam-gu, seoul South Koreaお知らせ • Feb 27Hyper Corporation Inc. has completed a Follow-on Equity Offering in the amount of KRW 14.999999 billion.Hyper Corporation Inc. has completed a Follow-on Equity Offering in the amount of KRW 14.999999 billion. Security Name: Common Stock Security Type: Common Stock Securities Offered: 8,556,759 Price\Range: KRW 1753 Transaction Features: Subsequent Direct Listingお知らせ • Dec 31Hyper Corporation Inc. announced that it has received KRW 34.999990179 billion in funding from UTXO Management GP, LLC, Fundpartner Solutions (Europe) SA, Woori Technology Investment Co., Ltd, Fanatic Strategic Holdings Pte. Ltd., Walkers Corporate Limited, Investment Arm, Kingsway Capital Partners LimitedOn December 30, 2025, Hyper Corporation Inc. closed the transaction.分析記事 • Dec 01Is Hyper (KOSDAQ:065650) A Risky Investment?David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...New Risk • Nov 14New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of South Korean stocks, typically moving 12% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (12% average weekly change). Earnings have declined by 36% per year over the past 5 years. Minor Risk Market cap is less than US$100m (₩41.0b market cap, or US$28.1m).お知らせ • Sep 17Bestand Korea agreed to acquire 89.32% stake in AI Mindbot Equity from Hyper Corporation Inc. (KOSDAQ:A065650) for KRW 8.5 billion.Bestand Korea agreed to acquire 89.32% stake in AI Mindbot Equity from Hyper Corporation Inc. (KOSDAQ:A065650) for KRW 8.5 billion on September 15, 2025. As part of the acquisition, Bestand Korea will acquire 0.021 shares AI Mindbot Equity. The consideration of KRW 8.5 billion will be paid in cash, out of which approximately KRW 850 million is paid as deposit on September 15, 2025 and the remaining KRW 7.6 billion will be paid upon completion of the acquisition. The transaction will be financed through Cash on hand and money borrowing. The expected completion of the transaction is November 7, 2025.New Risk • Aug 30New minor risk - Financial data availabilityLess than 3 years of financial data is available. This is considered a minor risk. If the company has been trading for less than 3 years, then it has not had the opportunity to establish a long-term track record. This makes it difficult for investors to assess the true growth potential, sustainability and resilience of the business under different economic conditions. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (27% average weekly change). Minor Risks Less than 3 years of financial data is available. Market cap is less than US$100m (₩58.4b market cap, or US$42.1m).お知らせ • Aug 08An undisclosed buyer agreed to acquire 19.49% stake in Makeus Co.,Ltd. from Hyper Corporation Inc. (KOSDAQ:A065650) for KRW 2.8 billion.An undisclosed buyer agreed to acquire 19.49% stake in Makeus Co.,Ltd. from Hyper Corporation Inc. (KOSDAQ:A065650) for KRW 2.8 billion on August 7, 2025. A cash consideration of KRW 2.8 billion will be paid by the buyer. As part of consideration, KRW 2.8 billion is paid towards common equity of Makeus Co.,Ltd. The expected completion of the transaction is December 31, 2025.分析記事 • Jun 26We Think Hyper (KOSDAQ:065650) Has A Fair Chunk Of DebtDavid Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Board Change • Jun 26Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 7 experienced directors. No highly experienced directors. 1 independent director (6 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.お知らせ • Mar 18Hyper Corporation Inc., Annual General Meeting, Mar 31, 2025Hyper Corporation Inc., Annual General Meeting, Mar 31, 2025, at 08:00 Tokyo Standard Time. Location: conference room, 117, gwacheon-daero 12-gil, gyeonggi-do, gwacheon South KoreaNew Risk • Feb 04New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 12% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Latest financial reports are more than 1 year old (reported December 2020 fiscal period end). Shareholders have been substantially diluted in the past year (106% increase in shares outstanding). Minor Risks Share price has been volatile over the past 3 months (12% average weekly change). Market cap is less than US$100m (₩73.2b market cap, or US$50.3m).お知らせ • Jun 01+ 2 more updatesMedifron DBT Co., Ltd. (KOSDAQ:A065650) completed the acquisition of 19.49% stake in Makeus Co.,Ltd. from FSN Co., Ltd. (KOSDAQ:A214270).Medifron DBT Co., Ltd. (KOSDAQ:A065650) agreed to acquire 19.49% stake in Makeus Co.,Ltd. from FSN Co., Ltd. (KOSDAQ:A214270) for KRW 7.9 billion on April 5, 2024. As per the transaction, Medifron DBT Co., Ltd. will acquire 4,963 shares of Makeus Co.,Ltd. The transaction will be financed from cash in hand. As of December 2023, Makeus Co.,Ltd. generated total assets of KRW 10.2 billion, total debt of KRW 4.4 billion, total capital KRW 5.8 billion and net loss KRW 403.4 million. Medifron DBT Co., Ltd. (KOSDAQ:A065650) completed the acquisition of 19.49% stake in Makeus Co.,Ltd. from FSN Co., Ltd. (KOSDAQ:A214270) on May 30, 2024.New Risk • May 10New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 78% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Latest financial reports are more than 1 year old (reported December 2020 fiscal period end). Shareholders have been substantially diluted in the past year (78% increase in shares outstanding). Minor Risks Share price has been volatile over the past 3 months (11% average weekly change). Market cap is less than US$100m (₩126.6b market cap, or US$92.7m).お知らせ • Apr 27Medifron DBT Co., Ltd. announced that it has received KRW 20.999999826 billion in funding from FSN Co., Ltd.On April 26, 2024, Medifron DBT Co., Ltd. closed the transaction.お知らせ • Feb 17Medifron DBT Co., Ltd. announced that it expects to receive KRW 41.999999652 billion in fundingMedifron DBT Co., Ltd. announces private placement of 41,420,118 shares at an issue price of KRW 1,014 for a gross proceeds of KRW 41,999,999,652 on February 15, 2024. The transaction is expected to close on April 30, 2024. The transaction has been approved by the board of the company.お知らせ • Feb 16Medifron DBT Co., Ltd. announced that it expects to receive KRW 20.999999826 billion in funding from FSN Co., Ltd.Medifron DBT Co., Ltd. announced a private placement of 20,710,059 common shares at a price of KRW 1,014 per share for the gross proceeds of KRW 20,999,999,826 on February 15, 2024. The transaction will include participation from new investor FSN Co., Ltd. The transaction has ben approved by the shareholders of the company is expected to close on April 26, 2024. The shares are restricted to a hold period of 1 year.New Risk • Feb 16New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 8.6% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Latest financial reports are more than 1 year old (reported December 2020 fiscal period end). Minor Risks Share price has been volatile over the past 3 months (8.6% average weekly change). Shareholders have been diluted in the past year (10.0% increase in shares outstanding). Market cap is less than US$100m (₩75.0b market cap, or US$56.4m).New Risk • Jul 12New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of South Korean stocks, typically moving 12% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Latest financial reports are more than 1 year old (reported December 2020 fiscal period end). Share price has been highly volatile over the past 3 months (12% average weekly change). Minor Risks Shareholders have been diluted in the past year (7.9% increase in shares outstanding). Market cap is less than US$100m (₩85.5b market cap, or US$66.3m).お知らせ • Dec 15Medifron DBT Co., Ltd. announced that it has received KRW 4.0000092 billion in funding from T Scientific Co.,LtdOn December 14, 2022, Medifron DBT Co., Ltd. closed the transaction. The company issued 3,427,600 shares in the transaction.Board Change • Nov 16Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 7 experienced directors. No highly experienced directors. 1 independent director (6 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.お知らせ • Aug 26Medifron DBT Co., Ltd. announced that it has received KRW 3 billion in fundingOn August 24, 2022, Medifron DBT Co., Ltd. closed the transaction.お知らせ • Aug 24Medifron DBT Co., Ltd. announced that it expects to receive KRW 3 billion in fundingMedifron DBT Co., Ltd. announced a private placement of series 12 unregistered coupon unguaranteed private convertible bond for gross proceeds of KRW 3,000,000,000 on August 22, 2022. The bonds carry 0% coupon rate, 0% yield to maturity, and will mature on August 24, 2027. The bonds are 100% convertible into 1,784,651 common shares of the company representing 3.93% stake, at a fixed conversion price of KRW 1,681 per share from August 24, 2023 till July 24, 2027. The subscription and payment date for the bonds is August 24, 2022. The transaction has been approved by the board of directors of the company. The bonds will be subject to a hold period of one year.お知らせ • Jun 23+ 2 more updatesMedifron DBT Co., Ltd. announced that it expects to receive KRW 5 billion in funding from Shinhan Financial Investment Co., Ltd., Mirae Asset Securities Co. Ltd., NH Investment & Securities Co., Ltd., KB Securities Co., Ltd.Medifron DBT Co., Ltd. announced a private placement of series 11 unregistered coupon non-guaranteed private convertible bond for gross proceeds of KRW 5,000,000,000 on June 22, 2022. The transaction will include participation from new investors Shinhan Financial Investment Co., Ltd. for KRW 1,500,000,000, Mirae Asset Securities Co. Ltd. for KRW 2,000,000,000,Pita KOSDAQ Venture General Private Equity Trust No.2, EIP ESG KOSDAQ Venture Specialized Investors General Private Equity Trust No. 1, funds managed by NH Investment & Securities Co., Ltd. for KRW 1,000,000,000, KY KOSDAQ Venture Specialized Investment Criminal Equity Trust No. 3 , fund managed by KB Securities Co., Ltd for KRW 500,000,000. The bonds carry 0% coupon rate, 0% yield to maturity, and will mature on June 30, 2027. The bonds are 100% convertible into 2,797,985 common shares of the company representing 6.42% stake, at a fixed conversion price of KRW 1,787 per share from June 30, 2023 till May 30, 2027. The subscription and payment date for the bonds is June 30, 2022. The transaction has been approved by the board of directors of the company. The bonds will be subject to a hold period of one year.Board Change • Apr 27Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 7 experienced directors. No highly experienced directors. 1 independent director (6 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.分析記事 • Mar 15Should Medifron DBT (KOSDAQ:065650) Be Disappointed With Their 48% Profit?While Medifron DBT Co., Ltd. ( KOSDAQ:065650 ) shareholders are probably generally happy, the stock hasn't had...Is New 90 Day High Low • Mar 08New 90-day low: ₩3,480The company is down 17% from its price of ₩4,200 on 08 December 2020. The South Korean market is up 8.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Electronic industry, which is up 19% over the same period.お知らせ • Feb 06Medifron DBT Co., Ltd. announced that it has received KRW 14.99999874 billion in funding from T Scientific Co., Ltd.On February 5, 2021, Medifron DBT Co., Ltd. (KOSDAQ:A065650) closed the transaction.Is New 90 Day High Low • Jan 28New 90-day low: ₩3,620The company is down 10.0% from its price of ₩4,030 on 30 October 2020. The South Korean market is up 32% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Electronic industry, which is up 56% over the same period.Is New 90 Day High Low • Dec 18New 90-day low: ₩3,985The company is down 20% from its price of ₩5,010 on 18 September 2020. The South Korean market is up 14% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Electronic industry, which is up 14% over the same period.お知らせ • Dec 02Medifron DBT Co., Ltd. announced that it expects to receive KRW 8 billion in fundingMedifron DBT Co., Ltd. (KOSDAQ:A065650) announced a private placement of series 9 domestic unregistered non-guaranteed private convertible bond for gross proceeds of KRW 8,000,000,000 on November 30, 2020. The transaction will include participation from new investor J&Giant Spice Private Equity Partnership. The bonds carry 0% coupon rate, 0% yield to maturity, will mature on December 4, 2023, and are 100% convertible into 1,777,777 common shares of the company representing 4.78% stake, at a fixed conversion price of KRW 4,500 per share from December 4, 2021 till November 4, 2024. The payment date for the bonds is December 4, 2020. The transaction has been approved by the board of directors of the company.分析記事 • Nov 29Despite Lacking Profits Medifron DBT (KOSDAQ:065650) Seems To Be On Top Of Its DebtSome say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Is New 90 Day High Low • Oct 19New 90-day low: ₩4,460The company is down 7.0% from its price of ₩4,810 on 21 July 2020. The South Korean market is up 7.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Electronic industry, which is up 6.0% over the same period.お知らせ • Sep 03Medifron DBT Co., Ltd. announced that it has received KRW 20 billion in funding from T.S. Investment CorporationOn September 1, 2020, Medifron DBT Co., Ltd. (KOSDAQ:A065650) closed the transaction.お知らせ • Aug 26Medifron DBT Co., Ltd. announced that it expects to receive KRW 20 billion in funding from T.S. Investment CorporationMedifron DBT Co., Ltd. (KOSDAQ:A065650) announced a private placement of series 8 domestic unregistered non-guaranteed private convertible bond for gross proceeds of KRW 20,000,000,000 on August 25, 2020. The transaction will include participation from new investor T.S. 2018-12 M&A Investment Fund, a fund managed by returning investor T.S. Investment Corporation (KOSDAQ:A246690). The bonds carry 0% coupon rate, 0% yield to maturity, will mature on September 01, 2025, and are 100% convertible into 3,998,400 common shares of the company representing 10.75% stake, at a fixed conversion price of KRW 5,002 per share from September 01, 2021 till August 01, 2025. The payment date for the bonds is September 01, 2020. The transaction has been approved by the board of directors of the company.財務状況分析短期負債: A065650の 短期資産 ( ₩45.4B ) は 短期負債 ( ₩50.6B ) をカバーしていません。長期負債: A065650の短期資産 ( ₩45.4B ) が 長期負債 ( ₩6.0B ) を上回っています。デット・ツー・エクイティの歴史と分析負債レベル: A065650の 純負債対資本比率 ( 118% ) は 高い と見なされます。負債の削減: A065650の負債対資本比率は、過去 5 年間で7.4%から237.1%に増加しました。債務返済能力: A065650の 営業キャッシュフロー はマイナスであるため、負債は十分にカバーされていません。インタレストカバレッジ: A065650の負債に対する 利息支払い が EBIT によって 十分にカバーされている かどうかを判断するにはデータが不十分です。貸借対照表健全な企業の発掘7D1Y7D1Y7D1YTech 業界の健全な企業。View Dividend企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/10 08:38終値2026/04/30 00:00収益2025/12/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Hyper Corporation Inc. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。1 アナリスト機関NaYeon KimMirae Asset Securities Co., Ltd.
分析記事 • Dec 01Is Hyper (KOSDAQ:065650) A Risky Investment?David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
分析記事 • Jun 26We Think Hyper (KOSDAQ:065650) Has A Fair Chunk Of DebtDavid Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
分析記事 • Nov 29Despite Lacking Profits Medifron DBT (KOSDAQ:065650) Seems To Be On Top Of Its DebtSome say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
New Risk • Apr 03New major risk - Financial positionThe company's debt is not well covered by operating cash flow. Currently running at an operating cash loss. This is considered a major risk. If the company's operating cash flows are too small relative to the size of their debt, it increases their balance sheet risk. The company has less cash from operations to cover its expenses from servicing large debt and it increases the risk of liquidity issues. It also extends the time it would take for the company to pay back the debt in full, meaning it may not be able to easily pay it all off in a distress scenario. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (currently running at an operating cash loss). High level of non-cash earnings (31% accrual ratio). Shareholders have been substantially diluted in the past year (64% increase in shares outstanding). Minor Risk Market cap is less than US$100m (₩43.1b market cap, or US$28.6m).
New Risk • Mar 26New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 64% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 34% per year over the past 5 years. Shareholders have been substantially diluted in the past year (64% increase in shares outstanding). Minor Risk Market cap is less than US$100m (₩43.2b market cap, or US$28.7m).
お知らせ • Mar 17Hyper Corporation Inc., Annual General Meeting, Mar 31, 2026Hyper Corporation Inc., Annual General Meeting, Mar 31, 2026, at 09:01 Tokyo Standard Time. Location: conference room, 637, eonju-ro, gangnam-gu, seoul South Korea
お知らせ • Feb 27Hyper Corporation Inc. has completed a Follow-on Equity Offering in the amount of KRW 14.999999 billion.Hyper Corporation Inc. has completed a Follow-on Equity Offering in the amount of KRW 14.999999 billion. Security Name: Common Stock Security Type: Common Stock Securities Offered: 8,556,759 Price\Range: KRW 1753 Transaction Features: Subsequent Direct Listing
お知らせ • Dec 31Hyper Corporation Inc. announced that it has received KRW 34.999990179 billion in funding from UTXO Management GP, LLC, Fundpartner Solutions (Europe) SA, Woori Technology Investment Co., Ltd, Fanatic Strategic Holdings Pte. Ltd., Walkers Corporate Limited, Investment Arm, Kingsway Capital Partners LimitedOn December 30, 2025, Hyper Corporation Inc. closed the transaction.
分析記事 • Dec 01Is Hyper (KOSDAQ:065650) A Risky Investment?David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
New Risk • Nov 14New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of South Korean stocks, typically moving 12% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (12% average weekly change). Earnings have declined by 36% per year over the past 5 years. Minor Risk Market cap is less than US$100m (₩41.0b market cap, or US$28.1m).
お知らせ • Sep 17Bestand Korea agreed to acquire 89.32% stake in AI Mindbot Equity from Hyper Corporation Inc. (KOSDAQ:A065650) for KRW 8.5 billion.Bestand Korea agreed to acquire 89.32% stake in AI Mindbot Equity from Hyper Corporation Inc. (KOSDAQ:A065650) for KRW 8.5 billion on September 15, 2025. As part of the acquisition, Bestand Korea will acquire 0.021 shares AI Mindbot Equity. The consideration of KRW 8.5 billion will be paid in cash, out of which approximately KRW 850 million is paid as deposit on September 15, 2025 and the remaining KRW 7.6 billion will be paid upon completion of the acquisition. The transaction will be financed through Cash on hand and money borrowing. The expected completion of the transaction is November 7, 2025.
New Risk • Aug 30New minor risk - Financial data availabilityLess than 3 years of financial data is available. This is considered a minor risk. If the company has been trading for less than 3 years, then it has not had the opportunity to establish a long-term track record. This makes it difficult for investors to assess the true growth potential, sustainability and resilience of the business under different economic conditions. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (27% average weekly change). Minor Risks Less than 3 years of financial data is available. Market cap is less than US$100m (₩58.4b market cap, or US$42.1m).
お知らせ • Aug 08An undisclosed buyer agreed to acquire 19.49% stake in Makeus Co.,Ltd. from Hyper Corporation Inc. (KOSDAQ:A065650) for KRW 2.8 billion.An undisclosed buyer agreed to acquire 19.49% stake in Makeus Co.,Ltd. from Hyper Corporation Inc. (KOSDAQ:A065650) for KRW 2.8 billion on August 7, 2025. A cash consideration of KRW 2.8 billion will be paid by the buyer. As part of consideration, KRW 2.8 billion is paid towards common equity of Makeus Co.,Ltd. The expected completion of the transaction is December 31, 2025.
分析記事 • Jun 26We Think Hyper (KOSDAQ:065650) Has A Fair Chunk Of DebtDavid Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
Board Change • Jun 26Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 7 experienced directors. No highly experienced directors. 1 independent director (6 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
お知らせ • Mar 18Hyper Corporation Inc., Annual General Meeting, Mar 31, 2025Hyper Corporation Inc., Annual General Meeting, Mar 31, 2025, at 08:00 Tokyo Standard Time. Location: conference room, 117, gwacheon-daero 12-gil, gyeonggi-do, gwacheon South Korea
New Risk • Feb 04New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 12% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Latest financial reports are more than 1 year old (reported December 2020 fiscal period end). Shareholders have been substantially diluted in the past year (106% increase in shares outstanding). Minor Risks Share price has been volatile over the past 3 months (12% average weekly change). Market cap is less than US$100m (₩73.2b market cap, or US$50.3m).
お知らせ • Jun 01+ 2 more updatesMedifron DBT Co., Ltd. (KOSDAQ:A065650) completed the acquisition of 19.49% stake in Makeus Co.,Ltd. from FSN Co., Ltd. (KOSDAQ:A214270).Medifron DBT Co., Ltd. (KOSDAQ:A065650) agreed to acquire 19.49% stake in Makeus Co.,Ltd. from FSN Co., Ltd. (KOSDAQ:A214270) for KRW 7.9 billion on April 5, 2024. As per the transaction, Medifron DBT Co., Ltd. will acquire 4,963 shares of Makeus Co.,Ltd. The transaction will be financed from cash in hand. As of December 2023, Makeus Co.,Ltd. generated total assets of KRW 10.2 billion, total debt of KRW 4.4 billion, total capital KRW 5.8 billion and net loss KRW 403.4 million. Medifron DBT Co., Ltd. (KOSDAQ:A065650) completed the acquisition of 19.49% stake in Makeus Co.,Ltd. from FSN Co., Ltd. (KOSDAQ:A214270) on May 30, 2024.
New Risk • May 10New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 78% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Latest financial reports are more than 1 year old (reported December 2020 fiscal period end). Shareholders have been substantially diluted in the past year (78% increase in shares outstanding). Minor Risks Share price has been volatile over the past 3 months (11% average weekly change). Market cap is less than US$100m (₩126.6b market cap, or US$92.7m).
お知らせ • Apr 27Medifron DBT Co., Ltd. announced that it has received KRW 20.999999826 billion in funding from FSN Co., Ltd.On April 26, 2024, Medifron DBT Co., Ltd. closed the transaction.
お知らせ • Feb 17Medifron DBT Co., Ltd. announced that it expects to receive KRW 41.999999652 billion in fundingMedifron DBT Co., Ltd. announces private placement of 41,420,118 shares at an issue price of KRW 1,014 for a gross proceeds of KRW 41,999,999,652 on February 15, 2024. The transaction is expected to close on April 30, 2024. The transaction has been approved by the board of the company.
お知らせ • Feb 16Medifron DBT Co., Ltd. announced that it expects to receive KRW 20.999999826 billion in funding from FSN Co., Ltd.Medifron DBT Co., Ltd. announced a private placement of 20,710,059 common shares at a price of KRW 1,014 per share for the gross proceeds of KRW 20,999,999,826 on February 15, 2024. The transaction will include participation from new investor FSN Co., Ltd. The transaction has ben approved by the shareholders of the company is expected to close on April 26, 2024. The shares are restricted to a hold period of 1 year.
New Risk • Feb 16New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 8.6% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Latest financial reports are more than 1 year old (reported December 2020 fiscal period end). Minor Risks Share price has been volatile over the past 3 months (8.6% average weekly change). Shareholders have been diluted in the past year (10.0% increase in shares outstanding). Market cap is less than US$100m (₩75.0b market cap, or US$56.4m).
New Risk • Jul 12New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of South Korean stocks, typically moving 12% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Latest financial reports are more than 1 year old (reported December 2020 fiscal period end). Share price has been highly volatile over the past 3 months (12% average weekly change). Minor Risks Shareholders have been diluted in the past year (7.9% increase in shares outstanding). Market cap is less than US$100m (₩85.5b market cap, or US$66.3m).
お知らせ • Dec 15Medifron DBT Co., Ltd. announced that it has received KRW 4.0000092 billion in funding from T Scientific Co.,LtdOn December 14, 2022, Medifron DBT Co., Ltd. closed the transaction. The company issued 3,427,600 shares in the transaction.
Board Change • Nov 16Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 7 experienced directors. No highly experienced directors. 1 independent director (6 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
お知らせ • Aug 26Medifron DBT Co., Ltd. announced that it has received KRW 3 billion in fundingOn August 24, 2022, Medifron DBT Co., Ltd. closed the transaction.
お知らせ • Aug 24Medifron DBT Co., Ltd. announced that it expects to receive KRW 3 billion in fundingMedifron DBT Co., Ltd. announced a private placement of series 12 unregistered coupon unguaranteed private convertible bond for gross proceeds of KRW 3,000,000,000 on August 22, 2022. The bonds carry 0% coupon rate, 0% yield to maturity, and will mature on August 24, 2027. The bonds are 100% convertible into 1,784,651 common shares of the company representing 3.93% stake, at a fixed conversion price of KRW 1,681 per share from August 24, 2023 till July 24, 2027. The subscription and payment date for the bonds is August 24, 2022. The transaction has been approved by the board of directors of the company. The bonds will be subject to a hold period of one year.
お知らせ • Jun 23+ 2 more updatesMedifron DBT Co., Ltd. announced that it expects to receive KRW 5 billion in funding from Shinhan Financial Investment Co., Ltd., Mirae Asset Securities Co. Ltd., NH Investment & Securities Co., Ltd., KB Securities Co., Ltd.Medifron DBT Co., Ltd. announced a private placement of series 11 unregistered coupon non-guaranteed private convertible bond for gross proceeds of KRW 5,000,000,000 on June 22, 2022. The transaction will include participation from new investors Shinhan Financial Investment Co., Ltd. for KRW 1,500,000,000, Mirae Asset Securities Co. Ltd. for KRW 2,000,000,000,Pita KOSDAQ Venture General Private Equity Trust No.2, EIP ESG KOSDAQ Venture Specialized Investors General Private Equity Trust No. 1, funds managed by NH Investment & Securities Co., Ltd. for KRW 1,000,000,000, KY KOSDAQ Venture Specialized Investment Criminal Equity Trust No. 3 , fund managed by KB Securities Co., Ltd for KRW 500,000,000. The bonds carry 0% coupon rate, 0% yield to maturity, and will mature on June 30, 2027. The bonds are 100% convertible into 2,797,985 common shares of the company representing 6.42% stake, at a fixed conversion price of KRW 1,787 per share from June 30, 2023 till May 30, 2027. The subscription and payment date for the bonds is June 30, 2022. The transaction has been approved by the board of directors of the company. The bonds will be subject to a hold period of one year.
Board Change • Apr 27Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 7 experienced directors. No highly experienced directors. 1 independent director (6 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
分析記事 • Mar 15Should Medifron DBT (KOSDAQ:065650) Be Disappointed With Their 48% Profit?While Medifron DBT Co., Ltd. ( KOSDAQ:065650 ) shareholders are probably generally happy, the stock hasn't had...
Is New 90 Day High Low • Mar 08New 90-day low: ₩3,480The company is down 17% from its price of ₩4,200 on 08 December 2020. The South Korean market is up 8.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Electronic industry, which is up 19% over the same period.
お知らせ • Feb 06Medifron DBT Co., Ltd. announced that it has received KRW 14.99999874 billion in funding from T Scientific Co., Ltd.On February 5, 2021, Medifron DBT Co., Ltd. (KOSDAQ:A065650) closed the transaction.
Is New 90 Day High Low • Jan 28New 90-day low: ₩3,620The company is down 10.0% from its price of ₩4,030 on 30 October 2020. The South Korean market is up 32% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Electronic industry, which is up 56% over the same period.
Is New 90 Day High Low • Dec 18New 90-day low: ₩3,985The company is down 20% from its price of ₩5,010 on 18 September 2020. The South Korean market is up 14% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Electronic industry, which is up 14% over the same period.
お知らせ • Dec 02Medifron DBT Co., Ltd. announced that it expects to receive KRW 8 billion in fundingMedifron DBT Co., Ltd. (KOSDAQ:A065650) announced a private placement of series 9 domestic unregistered non-guaranteed private convertible bond for gross proceeds of KRW 8,000,000,000 on November 30, 2020. The transaction will include participation from new investor J&Giant Spice Private Equity Partnership. The bonds carry 0% coupon rate, 0% yield to maturity, will mature on December 4, 2023, and are 100% convertible into 1,777,777 common shares of the company representing 4.78% stake, at a fixed conversion price of KRW 4,500 per share from December 4, 2021 till November 4, 2024. The payment date for the bonds is December 4, 2020. The transaction has been approved by the board of directors of the company.
分析記事 • Nov 29Despite Lacking Profits Medifron DBT (KOSDAQ:065650) Seems To Be On Top Of Its DebtSome say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
Is New 90 Day High Low • Oct 19New 90-day low: ₩4,460The company is down 7.0% from its price of ₩4,810 on 21 July 2020. The South Korean market is up 7.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Electronic industry, which is up 6.0% over the same period.
お知らせ • Sep 03Medifron DBT Co., Ltd. announced that it has received KRW 20 billion in funding from T.S. Investment CorporationOn September 1, 2020, Medifron DBT Co., Ltd. (KOSDAQ:A065650) closed the transaction.
お知らせ • Aug 26Medifron DBT Co., Ltd. announced that it expects to receive KRW 20 billion in funding from T.S. Investment CorporationMedifron DBT Co., Ltd. (KOSDAQ:A065650) announced a private placement of series 8 domestic unregistered non-guaranteed private convertible bond for gross proceeds of KRW 20,000,000,000 on August 25, 2020. The transaction will include participation from new investor T.S. 2018-12 M&A Investment Fund, a fund managed by returning investor T.S. Investment Corporation (KOSDAQ:A246690). The bonds carry 0% coupon rate, 0% yield to maturity, will mature on September 01, 2025, and are 100% convertible into 3,998,400 common shares of the company representing 10.75% stake, at a fixed conversion price of KRW 5,002 per share from September 01, 2021 till August 01, 2025. The payment date for the bonds is September 01, 2020. The transaction has been approved by the board of directors of the company.